These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25013123)

  • 21. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.
    Ishizawa J; Kojima K; McQueen T; Ruvolo V; Chachad D; Nogueras-Gonzalez GM; Huang X; Pierceall WE; Dettman EJ; Cardone MH; Shacham S; Konopleva M; Andreeff M
    PLoS One; 2015; 10(9):e0138377. PubMed ID: 26375587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW; van de Kooij B; Verheij M; Borst J
    Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
    Soderquist R; Pletnev AA; Danilov AV; Eastman A
    Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
    Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
    Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
    Pan R; Hogdal LJ; Benito JM; Bucci D; Han L; Borthakur G; Cortes J; DeAngelo DJ; Debose L; Mu H; Döhner H; Gaidzik VI; Galinsky I; Golfman LS; Haferlach T; Harutyunyan KG; Hu J; Leverson JD; Marcucci G; Müschen M; Newman R; Park E; Ruvolo PP; Ruvolo V; Ryan J; Schindela S; Zweidler-McKay P; Stone RM; Kantarjian H; Andreeff M; Konopleva M; Letai AG
    Cancer Discov; 2014 Mar; 4(3):362-75. PubMed ID: 24346116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
    Chonghaile TN; Roderick JE; Glenfield C; Ryan J; Sallan SE; Silverman LB; Loh ML; Hunger SP; Wood B; DeAngelo DJ; Stone R; Harris M; Gutierrez A; Kelliher MA; Letai A
    Cancer Discov; 2014 Sep; 4(9):1074-87. PubMed ID: 24994123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax).
    Lam LT; Lu X; Zhang H; Lesniewski R; Rosenberg S; Semizarov D
    Mol Cancer Ther; 2010 Nov; 9(11):2943-50. PubMed ID: 20829195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
    Del Gaizo Moore V; Schlis KD; Sallan SE; Armstrong SA; Letai A
    Blood; 2008 Feb; 111(4):2300-9. PubMed ID: 18056841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
    Opydo-Chanek M; Rak A; Cierniak A; Mazur L
    Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
    Subramanian A; Andronache A; Li YC; Wade M
    Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
    S Soderquist R; Eastman A
    Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells.
    Pallis M; Burrows F; Ryan J; Grundy M; Seedhouse C; Abdul-Aziz A; Montero J; Letai A; Russell N
    Oncotarget; 2017 Mar; 8(10):16220-16232. PubMed ID: 27092880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.